Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancer
Abstract: GS5-04
Researchers from The University of Texas MD Anderson Cancer Center have identified a standardized protocol that uses image-guided breast biopsies to reliably predict residual disease in breast cancer patients and that potentially identifies exceptional responders who may not require surgery. Utilizing this technique, a multicenter clinical trial led by Henry Kuerer, M.D., Ph.D., professor of Breast Surgical Oncology...
Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival
Abstract: GS5-01
Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of...
Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
Abstract: GS1-01
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition...
Acupuncture reduces radiation-induced dry mouth for cancer patients
After receiving acupuncture treatment three days a week during the course of radiation treatment, head and neck cancer patients experienced less dry mouth, according to study results from researchers at The University of Texas MD Anderson Cancer Center.
The trial results, published in JAMA Network Open, is the first randomized, placebo-controlled, Phase III trial to evaluate the use of acupuncture during radiation therapy to reduce...
Receiving care in a multidisciplinary prostate cancer clinic increases discussion about treatment options and adherence to national guidelines
Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their...
Study shows secondary surgery does not improve overall survival for recurrent ovarian cancer patients
Researchers from The University of Texas MD Anderson Cancer Center reported that secondary tumor-reduction, or cytoreduction, surgery followed...
MD Anderson statement regarding an assessment by the Centers for Medicare and Medicaid Services
For nearly 80 years, The University of Texas MD Anderson Cancer Center has been a global leader in the fight to end cancer. Our patients trust...
MD Anderson expanding its presence in The Woodlands
The University of Texas MD Anderson Cancer Center today opened its newest free-standing facility in The Woodlands. Serving patients in The...
Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations
Abstract: LBA32
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in...
PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
Abstract: LBA3
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment...
MD Anderson Cancer Center, First Tee team up to educate students nationwide on dangers of tobacco and e-cigarettes
The University of Texas MD Anderson Cancer Center, the official cancer center of the PGA TOUR, will attend the TOUR Championship for the fifth...
MD Anderson honored to rank as nation’s best hospital for cancer care in annual survey
The University of Texas MD Anderson Cancer Center is honored to be ranked No. 1 in cancer care in the U.S. News & World Report’s annual...
Darrow Zeidenstein, Ph.D., Named Chief Development Officer
The University of Texas MD Anderson Cancer Center today named Darrow Zeidenstein, Ph.D., as chief development officer. With more than 25 years...
Statement regarding surveys by the Centers for Medicare and Medicaid Services
The University of Texas MD Anderson Cancer Center has cooperated fully in two surveys conducted by the Centers for Medicare and Medicaid Services...
Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
ABSTRACT #7508
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination...
Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
ABSTRACT 8504
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response...
Ribociclib plus hormone therapy extends survival for patients with premenopausal advanced hormone receptor-positive breast cancer
ABSTRACT LBA1008
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal...
Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given...
Texas raises tobacco sales age to 21 to limit youth exposure and protect health
The University of Texas MD Anderson Cancer Center applauds the Texas Legislature today for passing Senate Bill 21, which raises the minimum...
Polo on the Prairie raises $775,000 for cancer research, patient care
Despite a Saturday morning storm that wreaked havoc on plans for this year’s Polo on the Prairie, May 18 at the Musselman Brothers’ Lazy 3...
Ipilimumab and nivolumab immunotherapy combination produces high response rate in metastatic bladder cancer
An immunotherapy combination with a higher dose of ipilimumab produced a 38 percent overall response rate for patients with metastatic bladder...
MD Anderson applauds Texas Legislature for authorizing continuation of CPRIT to support cancer research, education and prevention
The University of Texas MD Anderson Cancer Center applauds the 86th Texas Legislature today for voting to approve a constitutional amendment...
MD Anderson leadership development program receives first-of-its-kind accreditation
The University of Texas MD Anderson Cancer Center has received full accreditation by the American Association for Physician Leadership...
Study shows MD Anderson-developed drug effective in overcoming ibrutinib resistance in mantle cell lymphoma
A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered...
2019 Andrew Sabin Family Fellows share passion for Making Cancer History
The University of Texas MD Anderson Cancer Center has named eight researchers to the fourth annual class of Andrew Sabin Family Fellows. Each...
New cancer therapy target found in mitochondria for potential treatment of blood cancers
A study at The University of Texas MD Anderson Cancer Center identified a new therapeutic target in cancer cells and explains how new anti-cancer...
Study of tagraxofusp reports 90 percent response rate for deadly blood cancer with no prior available therapies
An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment...
Teen cancer patients prepare for an exciting night at annual Prom Party Palooza
HOUSTON – The University of Texas MD Anderson Children’s Cancer Hospital joins Peli Peli Restaurants, the National Association for Catering...
MD Anderson and Houston Dynamo to host End Cancer Night April 27
The University of Texas MD Anderson Cancer Center proudly presents End Cancer Night at BBVA Compass Stadium Saturday, April 27 at 7 p.m. as...
Single agent umbralisib effective for relapsed slow-growing lymphoma
A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients...
New potential therapeutic target for pancreatic cancer discovered
Cancer cells demand enormous amounts of molecular “food” to survive and grow, and a study published March 27 online in Nature by researchers...
Study may explain why immunotherapy not effective for some patients with metastatic melanoma and kidney cancer
White blood cells known as B cells have been shown to be effective for predicting which cancer patients will respond to immune checkpoint...
Study points to new strategy for boosting immunotherapy effectiveness in advanced colorectal cancer
Researchers at The University of Texas MD Anderson Cancer Center revealed the common oncogene KRAS as a possible explanation for why many...
MD Anderson's Making Cancer History Seminar heads to New Orleans
The University of Texas MD Anderson Cancer Center presents its Making Cancer History® Seminar, 11:30 a.m.-1:30 p.m. March 25 at the Hotel...
ZEB1 throttles therapeutic target, protecting KRAS-mutant lung cancer
A cellular identity switch protects a cancer-promoting genetic pathway from targeted therapy, researchers at The University of Texas MD Anderson...
MD Anderson to present Making Cancer History Seminar in Palm Beach
The University of Texas MD Anderson Cancer Center returns to Palm Beach with its Making Cancer History® Seminar, 9-11 a.m. March 18 at The...
Giulio Draetta named Chief Scientific Officer
The University of Texas MD Anderson Cancer Center has named Giulio Draetta, M.D., Ph. D. as chief scientific officer (CSO), a new position...
Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer according to study
A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test...
Study finds melanoma brain metastases are immunosuppressive with treatment-resistant metabolism
Melanoma tumors that have spread to the brain are equipped to thwart immunotherapies and targeted therapies that succeed against tumors growing...
New therapeutic target found for aggressive pediatric cancers with few treatment options
Researchers at The University of Texas MD Anderson Cancer Center have discovered that malignant rhabdoid tumors (MRT), a rare pediatric cancer...
MD Anderson supports World Cancer Day call for action to end cancer
As an institution devoted to eliminating cancer for patients in Texas, the nation and around the world, The University of Texas MD Anderson...
Rosanna Morris Joins MD Anderson as Chief Operating Officer from Beaumont Health
The University of Texas MD Anderson Cancer Center today named Rosanna Morris, RN, MBA, as chief operating officer (COO). With more than 20...
MD Anderson Cancer Center and Dragonfly Therapeutics announce strategic collaboration to take new immunotherapy candidates into clinical trials
The University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly...
Novel biomarker appears predictive of outcome in patients with HPV-related head and neck cancers
By analyzing variations in the level of human papillomavirus (HPV) in head and neck cancers, researchers at The University of Texas MD Anderson...
MD Anderson Cancer Center and Nanobiotix announce a large-scale, comprehensive clinical collaboration on NBTXR3
The University of Texas MD Anderson Cancer Center and Nanobiotix today announced a large-scale, comprehensive clinical research collaboration...
MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors
The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic...
MD Anderson notes passing of Waun Ki Hong – innovator, mentor, colleague
Waun Ki Hong, M.D., a trail-blazing physician-scientist and mentor whose clinical research innovations led to successful organ-sparing cancer...